Breast Neoplasms Clinical Trials in Stanford, California

3 studies are recruiting for breast neoplasms in Stanford, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study of LY4257496 in Participants With Cancer (OMNIRAY)

    The main purpose of this study is to evaluate safety, tolerability, and efficacy of LY4257496 alone and as part of relevant standard of care (SOC) combination therapy in participants with Gastrin-releasing Peptide Receptor (GRPR)-positive advanced cancer, including but not limited to breast, colore…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Stanford University Medical Center, Stanford, California
    Locations
    33 in total
    Run by
    Eli Lilly and Company

    See if you can join NCT07114601 on ClinicalTrials.gov

  2. A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

    This is a study of LY4337713 in participants with certain types of cancer that is advanced or has spread. Participants must have cancer with high levels of a protein called fibroblast activation protein (FAP). The purpose of this study is to evaluate safety, side effects, and efficacy of LY4337713.…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Stanford University Medical Center, Stanford, California
    Locations
    30 in total
    Run by
    Eli Lilly and Company

    See if you can join NCT07213791 on ClinicalTrials.gov

  3. A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

    The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload versus treatment of physician's choice (TPC) (paclitaxel, nab-paclitaxel, carboplatin plus gemcitabine, and capecitabine) fo…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Local Institution - 0358, Stanford, California
    Locations
    295 in total
    Run by
    Bristol-Myers Squibb

    See if you can join NCT06926868 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.